Ettore Luzi

Ettore Luzi

Auto-generated profile, based on publicly available information

Ettore Luzi

Metabolic Bone Unit, Department of Internal Medicine, University of Florence, Florence, Italy

Research Focus & Metrics

Academic Career Length

30Years (1997-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 February 2008 in Journal of Bone and Mineral Research
Verified
Journal Article
Open access
PDF file
ELEttore Luzi
Ettore Luzi
FMFrancesca Marini
Francesca Marini
SSSilvia Carbonell Sala
Silvia Carbonell Sala
ITIsabella Tognarini
Isabella Tognarini
GGGianna Galli
Gianna Galli
Maria Luisa BrandiMaria Luisa Brandi
Maria Luisa Brandi
The molecular mechanisms that regulate hADSC differentiation toward osteogenic precursors and subsequent bone-forming osteoblasts is unknown. Using osteoblast precursors obtained from subcutaneous human adipose tissue, we observed that microRNA-26a modulated late osteoblasts differentiation by targeting the SMAD1 transcription factor. Introduction: Elucidation of the molecular mechanisms guiding human adipose tissue-derived stem cells (hADSCs) differentiation is of extreme importance for improving the treatment of bone-related diseases such as osteoporosis. The aim of this study was to identify microRNA as a regulator of the osteogenic differentiation of hADSCs. Materials and Methods: Osteoblast differentiation of hADSCs was induced by treatment with dexamethasone, ascorbic acid, and β-glycerol phosphate. The expression of osteoblastic phenotype was evaluated after the induction by simultaneous monitoring of alkaline phosphatase activity, the expression of genes involved in osteoblastic differentiation by real-time RT-PCR, and mineralization at the same time. MicroRNA expression was determined by Northern blot, and transfection of both antisense miR-RNA and sensor plasmids was done to validate the inhibitory role of microRNA during hADSC osteogenesis. Western blot was used to determine the expression levels of the SMAD1 protein. qRT-PCR analysis was used to compare the expression patterns of osteoblastic markers in transfected cells. Results and Conclusions: We analyzed the role of microRNA 26a (miR-26a) during differentiation of hADSCs. Northern blot analysis of miR-26a during hADSC differentiation showed increased expression, whereas expression of the SMAD1 protein was complementary to that of miR-26a. Because the highest expression of miR-26a and the lowest expression of SMAD1 protein were reached at hADSC terminal differentiation, we carried out our study during the late stages of hADSC differentiation. The inhibition of miR-26a, by 2′-O-methyl-antisense RNA, increased protein levels of its predicted target, SMAD1 transcription factor, in treated osteoblasts, upregulating bone marker genes and thus enhancing osteoblast differentiation. Our data suggest a role for miR-26a in the differentiation induced by treatment with dexamethasone, ascorbic acid, and β-glycerol phosphate of hADSCs toward the osteogenic lineage by targeting its predicted target, the SMAD1 protein. This study contributes to a better knowledge of molecular mechanisms governing hADSC differentiation by proposing a microRNA-based control of late differentiation.

1 October 2005 in Bioelectrochemistry
Verified
Journal Article
Closed access
Sara TombelliSara Tombelli
Sara Tombelli
Maria MinunniMaria Minunni
Maria Minunni
ELE. Luzi
E. Luzi
MMM. Mascini
M. Mascini

1 December 2003 in TrAC Trends in Analytical Chemistry
Verified
Journal Article
Closed access
ELE. Luzi
E. Luzi
Maria MinunniMaria Minunni
Maria Minunni
Sara TombelliSara Tombelli
Sara Tombelli
MMM. Mascini
M. Mascini

1 December 2004 in Biosensors and Bioelectronics
Verified
Journal Article
Closed access
Maria MinunniMaria Minunni
Maria Minunni
Sara TombelliSara Tombelli
Sara Tombelli
AGA. Gullotto
A. Gullotto
ELE. Luzi
E. Luzi
MMM. Mascini
M. Mascini

2 October 2006 in Orphanet Journal of Rare Diseases
Verified
Journal Article
Open access
FMFrancesca Marini
Francesca Marini
ALBERTO FALCHETTIALBERTO FALCHETTI
ALBERTO FALCHETTI
FMFrancesca Del Monte
Francesca Del Monte
SSSilvia Carbonell Sala
Silvia Carbonell Sala
AGAlessia Gozzini
Alessia Gozzini
Maria Luisa BrandiMaria Luisa Brandi
Maria Luisa Brandi
Multiple Endocrine Neoplasia type 1 (MEN1) is a rare autosomal dominant hereditary cancer syndrome presented mostly by tumours of the parathyroids, endocrine pancreas and anterior pituitary, and characterised by a very high penetrance and an equal sex distribution. It occurs in approximately one in 30,000 individuals. Two different forms, sporadic and familial, have been described. The sporadic form presents with two of the three principal MEN1-related endocrine tumours (parathyroid adenomas, entero-pancreatic tumours and pituitary tumours) within a single patient, while the familial form consists of a MEN1 case with at least one first degree relative showing one of the endocrine characterising tumours. Other endocrine and non-endocrine lesions, such as adrenal cortical tumours, carcinoids of the bronchi, gastrointestinal tract and thymus, lipomas, angiofibromas, collagenomas have been described. The responsible gene, MEN1, maps on chromosome 11q13 and encodes a 610 aminoacid nuclear protein, menin, with no sequence homology to other known human proteins. MEN1 syndrome is caused by inactivating mutations of the MEN1 tumour suppressor gene. This gene is probably involved in the regulation of several cell functions such as DNA replication and repair and transcriptional machinery. The combination of clinical and genetic investigations, together with the improving of molecular genetics knowledge of the syndrome, helps in the clinical management of patients. Treatment consists of surgery and/or drug therapy, often in association with radiotherapy or chemotherapy. Currently, DNA testing allows the early identification of germline mutations in asymptomatic gene carriers, to whom routine surveillance (regular biochemical and/or radiological screenings to detect the development of MEN1-associated tumours and lesions) is recommended.

28 January 2010 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Closed access
PDF file
JVJohn P. Vessey
John P. Vessey
LSLucia Schoderboeck
Lucia Schoderboeck
EGEwald Gingl
Ewald Gingl
ELEttore Luzi
Ettore Luzi
JRJulia Riefler
Julia Riefler
PMPaolo Macchi
Paolo Macchi
In Drosophila , Pumilio (Pum) is important for neuronal homeostasis as well as learning and memory. We have recently characterized a mammalian homolog of Pum, Pum2, which is found in discrete RNA-containing particles in the somatodendritic compartment of polarized neurons. In this study, we investigated the role of Pum2 in developing and mature neurons by RNA interference. In immature neurons, loss of Pum2 led to enhanced dendritic outgrowth and arborization. In mature neurons, Pum2 down-regulation resulted in a significant reduction in dendritic spines and an increase in elongated dendritic filopodia. Furthermore, we observed an increase in excitatory synapse markers along dendritic shafts. Electrophysiological analysis of synaptic function of neurons lacking Pum2 revealed an increased miniature excitatory postsynaptic current frequency. We then identified two specific mRNAs coding for a known translational regulator, eIF4E, and for a voltage-gated sodium channel, Scn1a, which interacts with Pum2 in immunoprecipitations from brain lysates. Finally, we show that Pum2 regulates translation of the eIF4E mRNA. Taken together, our data reveal a previously undescribed role for Pum2 in dendrite morphogenesis, synapse function, and translational control.